Detalhe da pesquisa
1.
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.
Cell
; 175(4): 1014-1030.e19, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30343900
2.
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.
Cell
; 175(5): 1443, 2018 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30445041
3.
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.
Blood
; 143(16): 1646-1655, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38142448
4.
In vivo ablation of NFκB cascade effectors alleviates disease burden in myeloproliferative neoplasms.
Blood
; 2024 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38457657
5.
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Value Health
; 27(5): 607-613, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38311180
6.
Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms.
Am J Hematol
; 98(7): 1029-1042, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37203407
7.
Defining disease modification in myelofibrosis in the era of targeted therapy.
Cancer
; 128(13): 2420-2432, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35499819
8.
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Haematologica
; 107(7): 1599-1607, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551507
9.
Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.
Blood
; 134(11): 867-879, 2019 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31366621
10.
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Future Oncol
; 17(12): 1449-1458, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33423550
11.
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
N Engl J Med
; 375(21): 2023-2036, 2016 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27959731
12.
Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Haematologica
; 109(4): 3010, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38562076
13.
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
Haematologica
; 109(2): 676-681, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37259556
14.
A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
Br J Haematol
; 176(6): 939-949, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28220932
15.
Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib.
Br J Haematol
; 197(4): e49-e52, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35128632
16.
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
N Engl J Med
; 368(19): 1781-90, 2013 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-23656643
17.
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
J Natl Compr Canc Netw
; 13(4): 424-34, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25870379
18.
Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia.
N Engl J Med
; 375(5): 494-6, 2016 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27518686
19.
A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis.
Ther Adv Hematol
; 15: 20406207241237607, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38481947
20.
Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms.
Exp Hematol
; 132: 104178, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38340948